Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments (2016 - 2019)

Historic Long-Term Debt Repayments for Enanta Pharmaceuticals (ENTA) over the last 5 years, with Q3 2019 value amounting to $22000.0.

  • Enanta Pharmaceuticals' Long-Term Debt Repayments rose 1000.0% to $22000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was $86000.0, marking a year-over-year increase of 886.08%. This contributed to the annual value of $86000.0 for FY2019, which is 886.08% up from last year.
  • According to the latest figures from Q3 2019, Enanta Pharmaceuticals' Long-Term Debt Repayments is $22000.0, which was up 1000.0% from $22000.0 recorded in Q2 2019.
  • In the past 5 years, Enanta Pharmaceuticals' Long-Term Debt Repayments registered a high of $22000.0 during Q2 2019, and its lowest value of $16000.0 during Q4 2015.
  • Its 5-year average for Long-Term Debt Repayments is $19125.0, with a median of $19000.0 in 2017.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first surged by 1250.0% in 2016, then surged by 500.0% in 2019.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $16000.0 in 2015, then grew by 12.5% to $18000.0 in 2016, then rose by 5.56% to $19000.0 in 2017, then grew by 10.53% to $21000.0 in 2018, then rose by 4.76% to $22000.0 in 2019.
  • Its Long-Term Debt Repayments stands at $22000.0 for Q3 2019, versus $22000.0 for Q2 2019 and $21000.0 for Q1 2019.